Thursday, June 20, 2013

Intezyne acquires Niki Pharma

Intezyne Technologies has acquired Niiki Pharma. The acquisition gives Intezyne a Phase 2 asset being developed for non-pancreatic endocrine tumor. Niiki Pharma's GRP78 suppressor (NKP-1339), which has recently entered Phase 2 has the potential to enhance the treatment of neuroendocrine tumors and other tumor types. Currently there are no anti-tumor therapies that are approved for this specific type of cancer.
Tampa-based Intezyne is a privately held drug development company that focuses on improved cancer treatments. Niiki Pharma, based in Hoboken, N.J., is a similar drug development company.
Financial details of the acquisition were not disclosed.

About NKP-1339
NKP-1339 is a first-in-class small molecule anti-cancer compound that down-regulates GRP78, a known tumor survival and anti-apoptosis factor. In preclinical studies, NKP-1339 has demonstrated activity against multiple tumor types and has shown synergy with most cancer drugs.

About GRP78
GRP78 is a master-regulator of the cellular stress response. It is also a critical tumor cell survival, anti-apoptosis and resistance factor. In normal cells, GRP78 is found at low levels and located in the endoplasmic reticulum. In cancer cells, GRP78 is significantly up-regulated and found in the tumor cell cytoplasm, nucleus, endoplasmic reticulum, mitochondria, cell surface and is secreted. The elevation of GRP78 expression in a wide variety of cancer types has been correlated with increased tumor cell proliferation, metastasis, angiogenesis, and tumor cell survival and resistance. High levels of GRP78 protein have been correlated with primary and secondary resistance to many anti-cancer agents.





Enter your email address: Delivered by FeedBurner